

# The 35th NESS Speed Poster Presentation

*Overlap, Inverse Probability, and Matching Weights: What Are We Weighting For?*

**Yi Liu**

(Incoming) PhD student  
Department of Statistics  
North Carolina State University

May 23, 2022

# Introduction

- ▶ Propensity score (PS) weighting methods usually play a central role in drawing causal conclusions from observational data
- ▶ Some PS weights: overlap weights (OW), matching weights (MW), entropy weights (EW) and standard IPW weights. What should we expect when using them?
  - ▶ their estimands, target population, weights...
  - ▶ sensitivity to model misspecifications
- ▶ What is the role of the proportion of treated participants, i.e.  $p = P(Z = 1)$ , in estimating these estimands?

# Why do we care about the impact of $p$ ?

- ▶ When exposure is rare (small  $p$ ) and the treated population is of interest, ATT is encouraged, but ATE reaches extreme values and larger biases<sup>1</sup> to what we want
  - ▶ Rare exposure could be frequently encountered in pharmacoepidemiologic observational studies, study design does not require a high prevalence of exposure (EHR data, evaluation of newly approved drugs, etc.), ...
  - ▶ Then who is closer to ATT, which can also be useful in this case?
  - ▶ Similar issues may exist for ATC when  $p$  is large...

---

<sup>1</sup>D. Hajage, F. Tubach, P. G. Steg, *et al.*, “On the use of propensity scores in case of rare exposure,” *BMC medical research methodology*, vol. 16, no. 1, p. 38, 2016.

# Notation

- ▶ Treatment:  $Z = 0, 1$
- ▶ Covariates:  $\mathbf{X} = (X_1, \dots, X_p)'$
- ▶ Propensity score:  $e(\mathbf{x}) = P(Z = 1 | \mathbf{X} = \mathbf{x})$
- ▶ Potential outcome notation:  $Y(z), z = 0, 1$  – associated with the treatment assignment
- ▶ A generalized class of ATE–*weighted* ATE (WATE)<sup>2</sup>:

$$\tau_g = \frac{E[g(\mathbf{X})\tau(\mathbf{X})]}{E[g(\mathbf{X})]}$$

- ▶  $\tau(\mathbf{x}) = E[Y(1) - Y(0) | \mathbf{X} = \mathbf{x}]$ ;  $g(\mathbf{x})$ : *selection function* that re-distributes the covariates
- ▶ Different  $g$  defines different causal estimand and target population

---

<sup>2</sup>F. Li, K. L. Morgan, and A. M. Zaslavsky, “Balancing covariates via propensity score weighting,” *Journal of the American Statistical Association*, vol. 113, no. 521, pp. 390–400, 2018.

# Choice of $g$

**Table:** Choices of  $g$ , corresponding target population and causal estimands<sup>3</sup>

Target	$g(\mathbf{x})$	Estimand	Weights
overall	1	ATE	IPW
treated	$e(\mathbf{x})$	ATT	IPWT
control	$1 - e(\mathbf{x})$	ATC	IPWC
restricted	$\mathbf{1}\{\alpha \leq e(\mathbf{x}) \leq 1 - \alpha\}$	ATE	IPW and trimming
overlap	$e(\mathbf{x})(1 - e(\mathbf{x}))$	ATO	OW
overlap	$\min\{e(\mathbf{x}), 1 - e(\mathbf{x})\}$	ATM	MW
overlap	$-[e(\mathbf{x}) \ln(e(\mathbf{x})) + (1 - e(\mathbf{x})) \ln(1 - e(\mathbf{x}))]$	ATEN	EW

IPW: inverse probability weights;

OW (resp. MW, EW): overlap (resp. matching, entropy) weights;

We choose  $\alpha = 0.05, 0.1$  and  $0.15$ .

So, all  $g$  we considered is a function of  $e$ —the propensity score.

<sup>3</sup>R. A. Matsouaka and Y. Zhou, “A framework for causal inference in the presence of extreme inverse probability weights: The role of overlap weights,” *arXiv preprint arXiv:2011.01388*, 2020.

# Hájek-type Estimation

Data  $\{(X_i, Y_i, Z_i), i = 1, \dots, N\}$ .  $\tau_g = \frac{E[g(X)\tau(X)]}{E[g(X)]}$  can be estimated by the *Hájek-type estimator*

$$\hat{\tau}_g^H = \frac{\sum_{i=1}^N Z_i \hat{w}_1(\mathbf{x}_i) Y_i}{\sum_{i=1}^N Z_i \hat{w}_1(\mathbf{x}_i)} - \frac{\sum_{i=1}^N (1 - Z_i) \hat{w}_0(\mathbf{x}_i) Y_i}{\sum_{i=1}^N (1 - Z_i) \hat{w}_0(\mathbf{x}_i)}$$

$\hat{w}_z(\mathbf{x})$ ,  $z = 0, 1$  is calculated by a propensity score (PS) model (usually logistic regression).

Note: The *balancing weights*<sup>4</sup>:  $(w_0(\mathbf{x}), w_1(\mathbf{x})) \propto \left( \frac{g(\mathbf{x})}{1 - e(\mathbf{x})}, \frac{g(\mathbf{x})}{e(\mathbf{x})} \right)$

---

<sup>4</sup>F. Li, K. L. Morgan, and A. M. Zaslavsky, “Balancing covariates via propensity score weighting,” *Journal of the American Statistical Association*, vol. 113, no. 521, pp. 390–400, 2018.

# Augmented Estimation

Data  $\{(X_i, Y_i, Z_i), i = 1, \dots, N\}$ . The *augmented estimator* of  $\tau_g$  is given by

$$\hat{\tau}_g^{\text{aug}} = \frac{\sum_{i=1}^N g(\mathbf{x}_i) \{\hat{m}_1(\mathbf{x}_i) - \hat{m}_0(\mathbf{x}_i)\}}{\sum_{i=1}^N g(\mathbf{x}_i)} + \frac{\sum_{i=1}^N Z_i \hat{w}_1(\mathbf{x}_i) \{Y_i - \hat{m}_1(\mathbf{x}_i)\}}{\sum_{i=1}^N Z_i \hat{w}_1(\mathbf{x}_i)} - \frac{\sum_{i=1}^N (1 - Z_i) \hat{w}_0(\mathbf{x}_i) \{Y_i - \hat{m}_0(\mathbf{x}_i)\}}{\sum_{i=1}^N (1 - Z_i) \hat{w}_0(\mathbf{x}_i)}$$

where  $m_z(X) = E(Y(z)|X)$ ,  $z = 0, 1$  is an outcome regression (OR) model.

- ▶ Augmentation = Hájek-type + modeling the outcome
- ▶ For ATE, ATT and ATC, we can actually use their *doubly robust (DR) estimator*, which have better large-sample properties. For overlap estimands, augmented estimators are not DR.

# Sandwich Variance Estimation

- ▶ Both  $\hat{\tau}_g^H$  and  $\hat{\tau}_g^{\text{aug}}$  are consistent if the **PS model** is correctly specified<sup>5</sup>;
- ▶ Asymptotic normality under regularity conditions<sup>6</sup>:  

$$\sqrt{N}(\hat{\theta} - \theta) \xrightarrow{d} N(0, A(\theta)B(\theta)\{A(\theta)'\}^{-1});$$
- ▶ Score equation:

$$\sum_{i=1}^N \Psi_{\theta}(X_i, Z_i, Y_i) = \sum_{i=1}^N \begin{bmatrix} \psi_{\beta}(X_i, Z_i) \\ Z_i \psi_{\alpha_1}(X_i, Y_i) \\ (1 - Z_i) \psi_{\alpha_0}(X_i, Y_i) \\ g(X_i) \{m_1(X_i) - \tau_{1g}^m\} \\ g(X_i) \{m_0(X_i) - \tau_{0g}^m\} \\ Z_i w_1(X_i) (Y_i - m_1(X_i) - \mu_{1g}) \\ (1 - Z_i) w_0(X_i) (Y_i - m_0(X_i) - \mu_{0g}) \end{bmatrix} = 0$$

- ▶  $\theta = (\beta', \alpha_1', \alpha_0', \tau_{1h}^m, \tau_{0g}^m, \mu_{1g}, \mu_{0g})'$

---

<sup>5</sup>H. Mao, L. Li, and T. Greene, “Propensity score weighting analysis and treatment effect discovery,” *Statistical methods in medical research*, vol. 28, no. 8, pp. 2439–2454, 2019.

<sup>6</sup>A. W. Van der Vaart, *Asymptotic statistics*. Cambridge university press, 2000, vol. 3.



# Simulation - DGP

- ▶ 7 covariates  $\mathbf{X} = (X_1, X_2, \dots, X_7)'$  (following Li and Li<sup>7</sup>)
- ▶ Treatment:  $Z \sim \text{Bern}(\text{expit}(\mathbf{X}\beta))$  (logistic regression)
- ▶ Outcome model:  
 $Y(0) = 0.5 + X_1 + 0.6X_2 + 2.2X_3 - 1.2X_4 + (X_1 + X_2)^2 + \varepsilon$  and  
 $Y(1) = Y(0) + \delta(\mathbf{X})$ , for  $\varepsilon \sim N(0, 4)$  (linear regression)
  - ▶ True treatment effect:  $\delta(\mathbf{X}) = 4 + 3(X_1 + X_2)^2 + X_1X_3$
- ▶ Sample size  $N = 1000$  with 2000 replications
- ▶ We **only** consider model misspecifications for augmented estimators. For Hájek-type estimator, past research has shown that overlap estimators are more robust than the IPW estimator<sup>8</sup>.




---

<sup>7</sup>Y. Li and L. Li, “Propensity score analysis methods with balancing constraints: A monte carlo study,” *Statistical Methods in Medical Research*, vol. 30, no. 4, pp. 1119–1142, 2021.

<sup>8</sup>Y. Zhou, R. A. Matsouaka, and L. Thomas, “Propensity score weighting under limited overlap and model misspecification,” *Statistical Methods in Medical Research*, vol. 29, no. 12, pp. 3721–3756, 2020.

# Simulation - Propensity Score


- Generate 3 PS models, with small, middle and large  $p$




# Simulation - Point Estimation

True treatment effect:


$p$	$r$	ATE	ATE (0.05)	ATE (0.1)	ATE (0.15)	ATO	ATM	ATEN	ATC	ATT
20.77%	1.80	17.22	17.15	16.90	17.08	17.72	18.33	17.55	16.81	18.76
49.72%	1.13	17.22	17.20	17.12	16.91	16.69	16.30	16.81	16.61	17.83
79.59%	0.75	17.22	16.75	15.78	15.77	16.56	16.63	16.63	16.70	17.35




# Simulation - ARBias (%)



# Simulation - RMSE



# Simulation - Coverage Probability



# Simulation - Summary I: Sensitivity Assessment

- ▶ The IPW estimates (w/ or w/o trimming) for ATE sometimes have apparently larger biases and errors than overlap estimates for their estimands—more robust!
- ▶ The coverage probabilities suggest that the close-form sandwich variance formula works better for overlap estimands

## Simulation - Summary II: Impact of $p$

- ▶ When  $p$  is high, overlap estimators (ATO, ATM and ATEN) weight toward ATC (not exactly very close), and vice versa
- ▶ When  $p \approx 0.5$  and no extreme weights exist, IPW and overlap estimations are similar
- ▶ The **variances** of propensity scores of both treated and control groups also play a role—see my poster and a future publication!



# The impact of $p$ —is this really a surprise?

- ▶ First, clearly  $ATE = pATT + (1 - p)ATC$
- ▶ Second, the overlap weights ( $OW \propto (e(\mathbf{x}), 1 - e(\mathbf{x}))$ ), so<sup>9</sup>
  - ▶ when  $e(\mathbf{x}) \approx 0.5$ ,  $(e(\mathbf{x}), 1 - e(\mathbf{x})) \approx \left(\frac{0.25}{1-e(\mathbf{x})}, \frac{0.25}{e(\mathbf{x})}\right)$  (ATE weights)
  - ▶ when  $e(\mathbf{x})$  is small,  $(e(\mathbf{x}), 1 - e(\mathbf{x})) \approx \left(\frac{e(\mathbf{x})}{1-e(\mathbf{x})}, 1\right)$  (ATT weights)
  - ▶ when  $e(\mathbf{x})$  is large,  $(e(\mathbf{x}), 1 - e(\mathbf{x})) \approx \left(1, \frac{1-e(\mathbf{x})}{e(\mathbf{x})}\right)$  (ATC weights)
- ▶ Note  $p = P(Z = 1) = E[e(\mathbf{X})]$ , so we conjecture that under some conditions,  $p$ —the first moment of the propensity score, might reflect how overlap estimators weight ATT and ATC
- ▶ MW and EW are similar to  $OW$ <sup>10</sup>!

---

<sup>9</sup>F. Li, K. L. Morgan, and A. M. Zaslavsky, “Balancing covariates via propensity score weighting,” *Journal of the American Statistical Association*, vol. 113, no. 521, pp. 390–400, 2018.

<sup>10</sup>R. A. Matsouaka and Y. Zhou, “A framework for causal inference in the presence of extreme inverse probability weights: The role of overlap weights,” *arXiv preprint arXiv:2011.01388*, 2020.

## Data Example - treatment effects of RHC

- ▶ 5735 hospitalized patients enrolled a right heart catheterization (RHC) study
- ▶ **2184 (38%)** patients received the RHC treatment (small  $p$ )
- ▶ Outcome: log-length of stay during the first 24 hours in ICU

**Table:** Treatment effects of the RHC procedure on patients

Estimand	Prop.	Hájek-type Estimate			Augmented Estimate		
		Est.	SE	p-value	Est.	SE	p-value
ATE	100%	<b>0.130</b>	0.032	<0.001	<b>0.129</b>	0.033	<0.001
ATE (0.05)	93%	0.099	0.030	<0.001	0.102	0.030	<0.001
ATE (0.1)	82%	0.102	0.029	<0.001	0.100	0.029	<0.001
ATE (0.15)	73%	0.078	0.029	0.008	0.079	0.029	0.007
ATO	100%	<b>0.095</b>	0.028	<0.001	<b>0.098</b>	0.028	<0.001
ATM	100%	<b>0.094</b>	0.028	<0.001	<b>0.095</b>	0.028	<0.001
ATEN	100%	<b>0.100</b>	0.028	<0.001	<b>0.102</b>	0.028	<0.001
ATC	100%	<b>0.156</b>	0.035	<0.001	<b>0.148</b>	0.037	<0.001
ATT	100%	<b>0.090</b>	0.046	0.049	<b>0.099</b>	0.043	0.021

Prop.: proportion of sample used; Est.: point estimation; SE: standard error

## Concluding Remarks

- ▶ This work showed why sometimes ATE fails to identify the logical treatment effect, and provided some facts to researchers when they make choices according to what they want to accomplish
- ▶ Overlap estimators are overall more robust to model misspecifications, and have better coverage probabilities using the close-form sandwich variance estimations

# Upcoming Research

Variance estimation for equipoise treatment effect estimators (ATO, ATM, ATEN, BET)

- ▶ Sandwich
- ▶ Standard bootstrap
- ▶ Wild bootstrap (works very well for ATT and ATC!)
- ▶ ...

# References

- [1] D. Hajage, F. Tubach, P. G. Steg, D. L. Bhatt, and Y. De Rycke, “On the use of propensity scores in case of rare exposure,” *BMC medical research methodology*, vol. 16, no. 1, p. 38, 2016.
- [2] F. Li, K. L. Morgan, and A. M. Zaslavsky, “Balancing covariates via propensity score weighting,” *Journal of the American Statistical Association*, vol. 113, no. 521, pp. 390–400, 2018.
- [3] R. A. Matsouaka and Y. Zhou, “A framework for causal inference in the presence of extreme inverse probability weights: The role of overlap weights,” *arXiv preprint arXiv:2011.01388*, 2020.
- [4] H. Mao, L. Li, and T. Greene, “Propensity score weighting analysis and treatment effect discovery,” *Statistical methods in medical research*, vol. 28, no. 8, pp. 2439–2454, 2019.
- [5] A. W. Van der Vaart, *Asymptotic statistics*. Cambridge university press, 2000, vol. 3.
- [6] Y. Li and L. Li, “Propensity score analysis methods with balancing constraints: A monte carlo study,” *Statistical Methods in Medical Research*, vol. 30, no. 4, pp. 1119–1142, 2021.
- [7] Y. Zhou, R. A. Matsouaka, and L. Thomas, “Propensity score weighting under limited overlap and model misspecification,” *Statistical Methods in Medical Research*, vol. 29, no. 12, pp. 3721–3756, 2020.

### Variance estimation for the average treatment effects on the treated and on the controls.

Roland A. Matsouaka<sup>1,2</sup>, Yi Liu<sup>1</sup>, and Yunji Zhou<sup>1,3</sup>

Revision (April 17<sup>th</sup>): Statistical Methods in Medical Research

#### ARTICLE TYPE

### Overlap weights: what are we weighting for?

Roland A. Matsouaka<sup>1,2</sup> | Yi Liu<sup>1</sup> | Yunji Zhou<sup>1,3</sup>

Close to submit: Statistics in Medicine

Journal Title

XX(X):1-25

© The Author(s) 2019

Reprints and permission:

sagepub.co.uk/journalsPermissions.nav

DOI: 10.1177/ToBeAssigned

www.sagepub.com/

SAGE

# Acknowledgements

- ▶ Roland Matsouaka (Duke Biostatistics & Bioinformatics)
- ▶ Yunji Zhou (Duke Global Health Institute, Duke Biostatistics & Bioinformatics)
- ▶ Fan Li (Duke Statistical Science)
- ▶ Hwanhee Hong (Duke Biostatistics & Bioinformatics)

# Thank you!

Yi Liu

[yliu297@ncsu.edu](mailto:yliu297@ncsu.edu)